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ABSTRACT 
Previous animal model experiments have shown a correlation between interferon 
gamma (IFN) expression and both survival from infection with attenuated rabies 
virus and reduction of neurological sequelae.  Therefore, we hypothesized that 
rapid production of murine IFN by the rabies virus itself would induce a more 
robust antiviral response than would occur naturally in mice.  To test this 
hypothesis, we used reverse engineering to clone the mouse IFN gene into a 
pathogenic rabies virus backbone, SPBN, to produce the recombinant rabies 
virus designated SPBN.  Morbidity and mortality were monitored in mice infected 
intranasally with SPBN or SPBN(-) control virus to determine the degree of 
attenuation caused by the expression of IFN.  Incorporation of IFN into the 
rabies genome highly attenuated the virus.  SPBN has an LD50 more than 100 
fold greater than SPBN(-).  In vitro and in vivo mouse experiments show that 
SPBN infection enhances the production of type I interferons.  Furthermore, 
knockout mice lacking the ability to signal through the type I interferon receptor 
(IFNAR-/-) cannot control the SPBN infection and rapidly die.  These data 
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suggest that IFN production has antiviral effects in rabies, largely due to the 
induction of type I interferons. 
 
IMPORTANCE 
Survival from rabies is dependent upon the early control of virus replication and 
spread.  Once the virus reaches the CNS this becomes highly problematic.  
Studies of CNS immunity to RABV have shown that control of replication begins 
at the onset of T cell entry and IFN  production in the CNS prior to the 
appearance of virus-neutralizing antibodies. Moreover antibody deficient mice 
are able to control but not clear attenuated RABV from the CNS.  We find here 
that IFN triggers the early production of type I interferons with the expected  
antiviral effects.  We also show that engineering a lethal rabies virus to express  
IFN directly to the infected tissue reduces rabies virus replication and spread 
limiting its pathogenicity in normal and immunocompromised mice.  Therefore, 
vector delivery of IFN to the brain may have the potential to treat individuals who 
would otherwise succumb to infection with rabies virus.    
 
INTRODUCTION 
Rabies virus (RABV) is the type species of the lyssavirus genus in the 
rhabdoviridae family.  Its small, negative-stranded RNA genome encodes only 
five true genes (1, 2).  Although relatively simple, this zoonotic virus has a 
devastating impact worldwide.  The majority of human rabies deaths occur in 
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children in the developing world, and it is estimated that at least 55 000 humans 
die of rabies each year in Africa and Asia alone (3). 
 
Although RABV infection historically has been viewed as a death sentence once 
the virus reaches the brain, there is a small but growing number of humans who 
survived rabies even though the virus entered the brain (4, 5).  Due to such 
cases and to research using animal models of RABV infection (6–8), many 
believe that the immune system may be capable of clearing RABV from the brain 
without causing irreparable immunopathology.  It is clear, however, that 
therapeutic intervention will be necessary in the vast majority of cases.  Some 
theoretical or experimental rabies treatments involve slowing virus replication 
and/or spread by: induction of hypothermia (9); the highly controversial use of 
therapeutic coma (5); enhancing immune cell entry into the CNS (10); 
superinfection with an attenuated RABV (11, 12); and systemic or intrathecal 
administration of anti-viral drugs and interferons (IFN) (13).  For decades while 
many researchers have been studying the effects of type I IFN (predominantly 
IFN and ) during RABV infection our work has focused primarily on the role(s) 
of IFN during RABV clearance from the CNS.  
 
IFN is a pleiotropic cytokine and is the only known form of type II interferon.  
Although originally discovered by its ability to “interfere” with virus infection (14), 
its immunomodulatory functions were quickly recognized, and it is now widely 
accepted that IFN has many important functions in both innate and adaptive 
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immunity.  Some of these include: upregulation of adhesion molecules; activation 
of macrophages and NK cells; T cell activation and differentiation; upregulation of 
MHC molecules; antibody isotype switching; as well as induction of reactive 
oxygen species and reactive nitrogen intermediates (15).  These are merely a 
sample of what IFN induces as it is known to affect the expression of hundreds 
of genes (16).  Additionally, cross-talk between type I and type II IFN has been 
shown (17), suggesting IFN can amplify its anti-viral effects via the induction of 
type I IFN.  Furthermore, it is known that IFN can potentiate the action of type I 
IFN (18) and act synergistically with them (19).  Since its discovery, researchers 
and clinicians have been trying to harness IFN for its potential therapeutic 
effects.  It has been tested experimentally as an adjuvant in vaccines (20, 21) 
and as treatment in animal models of disease such as tuberculosis (22),  each 
with varying degrees of success.  Currently the only FDA-approved uses for IFN 
in humans are treatments for chronic granulomatous disease (23) and 
osteopetrosis (24), but IFN is also prescribed by veterinarians to treat canine 
atopic dermatitis (25).  These clinical uses of IFN highlight its pleiotropic nature 
as the mechanisms of action in these diseases are through enhanced innate 
immunity, activation of osteoclasts and suppression of the adaptive immune 
response, respectively. 
  
Our previous work has shown that IFN mRNA expression in the brains of mice 
infected with attenuated RABV strongly correlates with blood-brain barrier (BBB) 
permeability changes and clearance of RABV from the CNS (6, 26).  Recent 
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experiments confirm the importance of IFN during RABV clearance from the 
CNS, supporting the concept that IFN is at the center of the signaling pathway 
that alters tight junction protein expression and leads to increased BBB 
permeability and survival from RABV infection (27).  These rabies-specific data, 
as well as the more commonly known roles of IFN in the innate and adaptive 
arms of the immune response, suggest that therapeutically enhancing IFN 
expression in the CNS during a rabies infection may prevent virus spread and aid 
the clearance of RABV from CNS tissues through a number of mechanisms.  
Therefore, to more precisely determine the effects of IFN expression in the CNS 
on pathogenic RABV infection, we engineered a pathogenic RABV to express the 
murine IFN gene.   We report that RABV-expressed IFN highly attenuates a 
pathogenic RABV in mice, and that this attenuation is due, at least in part, to 
upregulation of type I IFN. 
 
MATERIALS AND METHODS: 
Mice.  Female Swiss Webster mice were purchased from Taconic Farms 
(Germantown, NY).  Female C57Bl/6J mice and IFN-/- mice on a C57Bl/6 
background were purchased from Jackson Laboratories (Bar Harbor, ME).  
WT129 and IFNAR-/- mice were from investigator breeding colonies maintained at 
Thomas Jefferson University and were originally provided by Michel Aguet (28).  
All mouse experiments were approved by the Thomas Jefferson University 
Institutional Animal Care and Use Committee. 
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Cell lines.  BSR cells (a BHK-21 clone) (29) grown in DMEM (Mediatech, 
Manassas, VA) supplemented with 10% FBS (Atlanta Biologicals, Flowery 
Ranch, GA) were used to grow virus stocks.  Mouse neuroblastoma cells (NA) 
were grown in RPMI medium 1640 (Mediatech, Manassas, VA) and used for 
growth curves, virus titers and immunofluorescence.  Mouse astrocytoma (AS) 
cells and monocyte lineage (MC) cells were grown in DMEM supplemented with 
10% FBS and were used for growth curves. 
 
Viruses.  SPBN, the prototype recombinant RABV was derived from the 
SADB19 strain (30, 31).  Although SPBN is often referred to as a vaccine vector, 
when administered to mice intranasally (i.n.), it is highly pathogenic.  The wild 
type RABV strain DRV4 was isolated from a human rabies victim and propagated 
in NA cells as previously described (32).   
 
Construction of recombinant viruses.  The recombinant RABVs, SPBN(-) and 
SPBN, were engineered as described previously (33).  For SPBN, murine IFN 
DNA was PCR-amplified from mRNA extracted from RABV-infected mouse brain 
tissue using the custom primers (IDT, Coralville, IA) below and DeepVent 
polymerase (NEB, Ipswich, MA).  The forward primer, 
5’ATAGAATTCCGTACGAAGATGAACGCTACACACTGCATCTTGGCT3’, 
contains a BsiWI restriction site, start codon, and the gene specific sequence.  
The reverse primer, 
5’ATTCTCTAGATAGCTAGCTCAGCAGCGACTCCTTTTCCGCTTCCT3’, 
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contains a NheI restriction site, stop codon, and the gene specific sequence.  
The resultant IFN DNA was cloned into the pSPBN plasmid, creating the 
pSPBN plasmid.  Standard transformation and transfection methods were used 
to complete the virus rescue of SPBN as outlined above. 
 
Growth Curves.  NA, AS or MC cells were infected at a multiplicity of infection 
(MOI) of 0.01 for multi-step and 1 for single-step growth curves.  100 ul 
supernatant aliquots were taken at 0, 24, 48 and 72 hours post-infection.  Virus 
titers from the supernatants were calculated as described below. 
 
Virus Titers.  To determine virus titers, NA cells were seeded into 96 well plates, 
grown for two days and then infected with virus in serial ten-fold dilutions.  Two 
days post-infection (d.p.i.), the cells were fixed with 80% acetone and stained 
with FITC-conjugated anti-RABV RNP antibody (Fujirebio Diagnostics, Malvern, 
PA). Virus titers of triplicate samples were determined using a fluorescence 
microscope. 
 
Immunofluorescent staining.  NA cells were grown in culture well slides for 24 
hours and then infected with RABV at an MOI=0.1.  24 hours later, cells were 
stained for the presence of RABV and mouse IFN using FITC-conjugated anti-
RABV RNP antibody and PE-conjugated anti-mouse IFN antibody (Sigma, St. 
Louis, MO), respectively.  Slides were mounted using ProLong Gold with DAPI 
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(Life Technologies, Eugene, OR).  Photos were taken using a DM6000B 
fluorescent microscope (Leica, Buffalo Grove, IL). 
 
Infection of mice.  Groups of mice were infected under isoflurane (Vedco, St. 
Joseph, MO) anesthesia: intracranially (i.c.) with 103 focus-forming units (ffu) in 
10 ul PBS or intranasally (i.n.) with 103-106 ffu in 20 ul PBS.  Mice were observed 
for at least 30 days for appearance of clinical signs of rabies such as limb 
paralysis, tremors and weight loss.  Mice were humanely euthanized when 
moribund or after losing greater than 30% of starting body weight.  
 
IFNTreatment.  Cells were treated with 10, 100 or 1000U of recombinant mouse 
IFN (BD Biosciences, San Jose, California) at 24 and 48 hours post-infection by 
addition to the culture medium. 
 
Enzyme-Linked Immunosorbent Assay (ELISA).  50 ul aliquots of virus-
infected supernatants were assayed for IFN using an OptEIA Mouse IFN Kit II 
(BD Biosciences, San Jose, CA) or for IFN using a Mouse IFN-alpha Platinum 
ELISA kit (eBioscience, Vienna, Austria) per manufacturers’ instructions.  The 
plates were then scanned in a Synergy H1 plate reader (BioTek, Winooski, VT) 
and absorbance at 450 nm was recorded. 
 
Quantitative PCR.  RNAtot was extracted from brain samples using a Qiagen 
RNeasy kit (Qiagen, Valencia, CA) and modified Qiagen protocol previously 
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described (6).  Briefly, tissues were homogenized by aspirating through a sterile, 
20 gauge needle approximately 15 times in TriReagent (MRC, Cincinnati, OH).  
Homogenized samples were spun in a Heraeus Biofuge pico benchtop centrifuge 
(Thermo Scientific, Langenselbold, Germany) at 12 000 rpm for 15 min at RT.  
The aqueous layer was removed and mixed with an equal portion of 70% ethanol 
and then added to the Qiagen spin column.  All subsequent steps are outlined in 
the Qiagen manual, including the optional on-column DNAse I digestion which 
was used.  After RNAtot extraction, cDNA was prepared using oligo dT15 primers, 
dNTP and Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, 
Madison, WI) as described previously (6).  Finally, each sample was analyzed for 
the presence of specific mRNAs by qPCR using a Biorad iCycler, iQ Supermix or 
iQ Sybr (BioRad, Hercules, CA), and primer/probe sets (IDT, Coralville, IA) 
designed as follows: CD4 F AGGTCTCGCTTCAGTTTGCT, R 
AGCCACTTTCATCACCACCA, Pr TGGCAACCTGACTCTGACTCTGGACA; 
CD8 F CATCCTGCTTCTGCTGGCATT, R TGGGCGCTGATCATTTGTGAAA, Pr 
TGTGTGCGGAGGAGAGCCCGAATTCA; CD19 F 
GAGCTCAGAGCCATGAAACA, R CAAGGTTGGAGTCGTTCTCA, Pr 
CCAGACAGCGAGGAGGGCTCTGAAT; IFN F 
AGCAACAACATAAGCGTCATT, R CCTCAAAACTTGGCAATACTCA, Pr 
ACCTTCTTCAGCAACAGCAAGGGC; SPBN-N F 
AGAAGGGAATTGGGCTCTG, R TGTTTTGCCCGGATATTTTG, Pr 
CGTCCTTAGTCGGTCTTCTCT; L13 F CTACAGTGAGATACCACACCAAG, R 
TGGACTTGTTTCGCCTCCTG, Pr ATCCACAAGAAAGTGGCTCGCACCAT; 
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IFN F ATTTTGGATTCCCCTTGGAG, R TGATGGAGGTCATTGCAGAA; IFN 
F CACAGCCCTCTCCATCAACT, R GCAACCACCACTCATTCTGA. 
 
Statistical Analysis.  All calculations were performed using GraphPad Prism 
5.01 (GraphPad Software, San Diego, CA) with the exception of the Habel Test 
for Potency (34). 
 
RESULTS 
Recombinant rabies virus expresses murine IFN.  Recombinant RABVs were 
constructed using the pathogenic SPBN backbone vector.  Fig. 1A shows a wild-
type RABV genome while 1C depicts the IFN-expressing SPBN, termed SPBN.  
To control for any changes in replication efficiency that might occur due to 
increased size of the RABV genome, we used the previously constructed SPBN(-
) (Fig. 1B).  SPBN(-) has an inactivated tumor necrosis factor  (TNF) gene in 
lieu of murine IFN.  
 
To ensure that SPBN can produce murine IFN, we infected NA cells grown on 
culture well slides with SPBN or SPBN(-) at an MOI =0.1.  24 hours p.i. the cells 
were fixed, permeabilized and stained for evidence of RABV infection and murine 
IFN production.  Fig. 2 shows the results of immunostaining for RABV and IFN 
of uninfected (A), SPBN(-) (B) and SPBN (C) infected NA cells.  While cells 
infected with SPBN(-) are positive only for RABV, the SPBN-infected cells 
stained positive for both RABV and IFN, demonstrating that our recombinant 
 12 
SPBN produces IFN. We next used ELISA to analyze the supernatants of NA, 
AS and MC cell lines infected with SPBN or SPBN(-) for the presence of IFN.  
Fig. 2D shows that by 12 hours p.i. significant amounts of IFN are produced and 
secreted into the supernatants of all cell types infected with SPBN but not 
SPBN(-). 
 
Virus-encoded IFN has differential effects on RABV replication in vitro.  To 
determine the effects of IFN expression on RABV replication in relevant cell 
types, we infected NA, AS and MC cell lines with SPBN or SPBN(-) (Fig. 3)  As 
shown in Fig. 3A and 3D, there is less than one log10 difference in virus 
replication and spread between SPBN and SPBN(-) in NA cells by 48 hours p.i.  
Both viruses grow to relatively high titers (>107 ffu/ml).  In AS cells there is a 
similar result with less than one log10 difference in growth by 48 hours p.i. in the 
single-step growth curve (Fig. 3B).  IFN production may slow the spread of 
SPBN in AS cells, however, as there is greater than one log10 difference 
between the virus titers at 72 hours p.i. (Fig. 3E).  In contrast to the minor 
differences seen in NA and AS cell lines, the replication rate and spread of 
SPBN in MC cells is several logs10 lower as compared to SPBN(-) (Fig. 3C, 3F).  
The antiviral mechanisms in the MC cells appear to be very rapidly activated, as 
this multi-log difference in replication is evident as early as 24 hours p.i.  This 
significant decrease in SPBN replication as compared to SPBN(-) indicates that 
the IFN produced by SPBN and measured by ELISA (Fig. 2D) is indeed 
functional.  Although SPBN replication is hampered in MC cells, substantial 
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numbers of progeny virions (~103 ffu/ml) were still produced, indicating that even 
in an immune cell line highly responsive to IFN, SPBN is able replicate and 
spread.   
 
IFN attenuates pathogenic RABV.  After demonstrating the ability of SPBN to 
replicate well in permissive cells and produce IFN in vitro, we examined the 
pathogenicity of SPBN(-) and SPBN in vivo.  Groups of ten Swiss-Webster mice 
were infected i.n. with 103 – 106 ffu of SPBN or SPBN(-).  Mice were monitored 
for mortality and morbidity for 30 days.  The resultant survivorships (Fig. 4A and 
4C) clearly demonstrate the attenuation of the pathogenic SPBN vector by the 
addition of IFN to its genome.  The most striking difference in pathogenicity 
occurs at 105 ffu where 90% of SPBN mice survive infection while 100% of mice 
infected with SPBN(-) succumb within 15 days, but SPBN is significantly 
attenuated at all doses compared to SPBN(-).  To quantify the attenuation of 
pathogenicity due to IFN, we calculated the LD50 of SPBN and SPBN(-) and 
found greater than a two log10 difference between the viruses (Fig. 4B).  It should 
be noted that the exact difference could not be calculated because infection with 
all doses of SPBN(-) killed more than 50% of the mice.  Thus, the expression of 
IFN from the RABV genome decreased the pathogenicity of SPBN by more than 
100 fold when administered i.n.   
 
SPBN replication is diminished while IFN expression is elevated in the 
CNS of infected mice.  Having demonstrated that IFN expression by RABV has 
 14 
differential effects on virus replication in various cell types in vitro, we next 
infected groups of C57BL/6 mice with SPBN or control SPBN(-) to quantify virus 
replication and IFN gene expression in the CNS.  At 10 d.p.i. viral nucleoprotein 
(N) RNA expression in both the cerebellum and cortex is approximately ten fold 
lower in mice infected with SPBN than SPBN(-) (Fig. 5A).  Despite the reduced 
replication, the cerebellum and cortex of the SPBN-infected mice showed 
approximately ten fold greater IFN mRNA levels than in SPBN(-)-infected mice 
(Fig. 5B).  Taken together, these data show that at 10 d.p.i. SPBN induces 
greater than 100 fold more IFN expression per viral N message in the CNS of 
mice than SPBN(-) (Fig. 5C). 
 
SPBN infection does not increase immune cell infiltration into the CNS.  In 
other animal models, immune cell infiltration into the CNS has been shown to be 
essential for RABV clearance (eg. 8, 35).  To determine whether enhanced 
immune cell infiltration could play a role in the attenuation of SPBN, we 
measured the expression of mRNA specific for CD4+, CD8+ and CD19+ cells as 
an estimation of T and B cell influx into the CNS of mice infected with SPBN or 
SPBN(-) (Fig.6).  At 10 d.p.i. we found no significant increase in immune cell 
markers in the brains of SPBN-infected as compared to SPBN(-)-infected mice.  
In fact, the SPBN(-)-infected mice showed increased expression of T cell marker 
CD8 in both the cerebellum (CB) and cortex (CX).  
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SPBN attenuation occurs in the absence of endogenous IFN or 
antibodies.  Previously it has been suggested that IFN-producing T cells as well 
as virus-neutralizing antibodies (VNA) are important for the clearance of RABV 
from the brain (36, 37).  To determine if endogenously produced IFN or VNA are 
essential for SPBN attenuation, we infected groups of IFN-/- mice, having no 
endogenous IFN, and groups of JHD
-/- mice, lacking functional B cells and 
antibodies, with SPBN or SPBN(-).  At 16 d.p.i. 100% of SPBN-infected IFN-/- 
mice were alive compared to only 11% of those infected with SPBN(-) (Fig. 7A).  
We continued to monitor the mice until 35 d.p.i., at which time 75% of IFN-/- mice 
infected with SPBN remained alive while only 11% of SPBN(-)-infected mice 
survived.  As seen in Fig. 7B, SPBN(-)-infected IFN-/- mice also begin to lose 
weight earlier than their SPBN-infected counterparts.   
 
The importance of antibody to RABV clearance from the brain is well established.   
Therefore, we infected JHD
-/- mice to determine if IFN overexpression could 
prevent or delay death in the absence of antibody.  Infection of JHD
-/- mice yields 
a similar outcome to that seen with IFN-/- mice.  By 17 d.p.i. all SPBN(-)-infected 
JHD
-/- mice succumbed to rabies infection while 100% of those infected with 
SPBN remained alive (Fig. 7C).  By the end of the experiment, at 32 d.p.i., 92% 
of JHD
-/- mice infected with SPBN survived, despite having no functional, 
circulating antibodies.  As can be expected, the mice infected with SPBN(-) lost 
weight faster than those infected with SPBN (Fig. 7D).  Although most of the 
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mice were sacrificed at day 32, we continued to monitor five SPBN-infected 
JHD-/- mice.  Surprisingly, 5 of 5 of these mice survived for 75 days, 4 of 5 
survived 87 days, and 3 of 5 remained alive for 88 days, at which time this 
experiment was concluded (data not shown).  Thus even this severe immune 
deficit does not prevent long-term control of SPBN infection by the host.   
 
IFNAR-/- mice do not survive SPBN infection.  IFNAR-/- mice are 
unresponsive to type I IFN because the IFNAR1 chain of the heterodimeric 
receptor is knocked out (28).  Based on knowledge that IFN can potentiate type 
I IFN effects as well as act synergistically with type I IFN, we infected groups of 
IFNAR-/- mice, as well as their background control WT129 mice, with SPBN or 
SPBN(-) to determine the role of type I IFN in attenuation of SPBN.  100% of 
IFNAR-/- die from infection with SPBN by 14 d.p.i., and this is not significantly 
different from the control SPBN(-)-infected IFNAR-/- mice which all die by 13 
d.p.i..  The WT129 background does not significantly alter the strong attenuation 
of SPBN seen in Swiss-Webster mice as 86% of SPBN-infected WT129 mice 
survive for 31 days while 100% of these animals infected with SPBN(-) die.  
 
SPBN induces early Type I IFN expression in vitro and in vivo. There is 
substantial overlap in the regulation of type I and type II IFN (38).  The early or 
increased expression of IFN by SPBN may increase the expression of type I 
IFN, thereby enhancing the innate immune response to RABV and protecting 
mice from death during SPBN infection.  To test this theory, we infected flasks of 
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MC cells with SPBN or SPBN(-) and measured virus- and IFN-specific mRNA 
levels in these cells at various timepoints post-infection.  Infection of MC cells 
with SPBN leads to an early and sustained overexpression of IFN (Fig. 9A) and 
induces a significant increase in IFN expression as compared to SPBN(-) 
infection from 6 to 48 hours p.i. (Fig. 9B).  This effect is also seen when 
measuring IFN induction (Fig. 9C), however, IFN expression continues to rise 
in the SPBN(-)-infected MC cells, becoming significantly higher in these cultures 
by 24 hours p.i.  The increase in type I IFN expression in SPBN(-)-infected MC 
cells during the later timepoints is most likely the result of more rapid virus 
replication, as evidenced by the viral N message levels (Fig. 9A-C).  SPBN 
replication remains very low throughout the experiment but induces relatively 
high type I and type II IFN expression.  The addition of IFN to cultures of  
SPBN(-)-infected MC cells reduces viral replication (Fig. 9D) in concert with 
increasing IFN levels (Fig. 9E) at early timepoints.  Elevated IFN levels, which 
are only seen in the presence of both IFN and virus infection, are particularly 
evident at 24 hrs of culture (Fig. 9F). 
 
To determine if SPBN also induces higher levels of type I IFN in the brain than 
SPBN(-), we infected groups of C57BL/6 mice with either virus.  We sacrificed 
the mice at early timepoints during infection and analyzed the samples by qPCR 
for the presence of viral RNA as well as type I and type II IFN mRNA.  It is widely 
held that IFN expression levels increase as virus replication increases (39).  In 
fact, mice dying from RABV and other related viruses, often have highest levels 
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of circulating IFN just before death (40).  Therefore, we compared IFN 
expression levels to the amount of virus replication in the olfactory bulb (OB) 
(Fig. 10A,D,G), cerebellum (CB) (Fig. 10B,E,H) and cerebral cortex (CX) (Fig. 
10C,F,I) of infected mice.  After normalizing the IFN message levels to RABV N 
mRNA, it is clear that SPBN induces significantly higher levels of IFN (Fig. 10A-
C) and type I IFN (Fig. 10D-I) per viral message than does SPBN(-).  Relative 
levels of IFN, IFN and IFN expression were significantly increased in SPBN-
infected OB at 4, 6 and 8 d.p.i. as compared to SPBN(-)-infected OB (Fig. 
10A,D,G).  In the CB and CX, expression of type I IFN was significantly 
increased at 6 and 8 d.p.i. (Fig. 10E,F,H,I).  No SPBN virus was detected in 
these samples at day 4 p.i. likely due to the time required for the spread of 
SPBN to those brain regions from the OB.  The relative level of IFN was 
significantly increased in SPBN-infected CB at 8 d.p.i. (Fig. 10B) and both 6 and 
8 d.p.i. in the CX (Fig. 10C), as compared to SPBN(-)-infected tissues. 
 
DISCUSSION. 
IFN is a pleiotropic cytokine capable of modulating both the innate and adaptive 
immune responses and, as hypothesized, the addition of murine IFN to the 
genome of SPBN highly attenuated the pathogenicity of this virus in mice.  To 
determine which IFN-inducible antiviral mechanism(s) led to the strong 
attenuation of the RABV, we infected cell lines relevant to RABV infection as well 
as wild-type mice and knock-out mice with specific immune deficits.  Together 
the data support the concept that IFN production by SPBN attenuates the virus 
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by enhancing the production of type I IFNs early in the infection.  Thus IFN, an 
important product of adaptive immunity, inhibits RABV replication by  activating 
well-established innate antiviral mechanisms. 
  
We previously showed a significant correlation exists among IFN expression, 
BBB permeability and RABV clearance from the CNS (6, 26).  The changes in 
BBB permeability are necessary to allow immune effectors to enter the CNS and 
eliminate the RABV infection.  Various studies suggest that the mechanism 
involves IFN-mediated induction of radicals (26, 41), which culminates in the 
alteration of tight-junction proteins (27).  In the present study, however, we did 
not observe an increase in BBB permeability due to IFN overexpression.  While 
pathogenic when administered intranasally, the control SPBN(-) virus, unlike 
wild-type RABV (42), induces BBB permeability and allows immune cells to 
infiltrate the brain.  In fact, we showed that SPBN(-) infection resulted in a 
significant increase in immune cell markers in some brain regions as compared 
to SPBN infection, despite having much lower levels of IFN expression.  This 
seemingly paradoxical result is most likely the result of decreased SPBN 
replication necessitating the influx of fewer immune cells to clear the infection, as 
compared to the SPBN(-) infection.  Since SPBN(-) is pathogenic, despite 
triggering functional changes in the BBB and immune cell invasion into the 
infected CNS, we can conclude that viral IFN expression has additional 
therapeutic effects on RABV infection. 
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Since it is known that production of VNA is important for protection against RABV 
infection, and IFN is capable of affecting the humoral adaptive response against 
viruses, we studied SPBN infection in JHD
-/- mice which have no functional B 
cells and produce no antibodies.  Interestingly, the substantial attenuation of 
SPBN is not the result of earlier or greater production of antibodies, as 
evidenced by the survival of 92% of SPBN-infected B cell deficient mice 32 d.p.i. 
In actuality, addition of IFN to a vaccine RABV strain could even suppress VNA 
induction due to lower viral replication.  Our data support the concept that 
circulating antibody may not be the best indicator of vaccine efficacy as IFN 
could be affecting T cell memory or memory in other cell types that are not 
evident when judging vaccine efficacy only by the induction of serum VNA (43).  
It should be noted that antibody is not required for long-term survival from RABV 
in the context of IFN overexpression in our experiments.  Nevertheless, these 
data do not refute the numerous reports that VNA are essential for the clearance 
of RABV in the absence of such therapeutic intervention.   
 
Previous findings suggest that IFN-producing T cells play an important role in 
the clearance of RABV (6, 26, 36, 44), as well as other neurotropic viruses (45, 
46), from the CNS of mice.  Additionally, little is known about the role of NK-
derived IFN during RABV infection.  To determine if the cellular source of IFN is 
essential for a therapeutic effect, we infected IFN-/- mice with SPBN(-) or 
SPBN.   We found that the majority of SPBN-infected mice survived while 
SPBN(-)-infected IFN-/- mice did not.  Since we used i.n. infection, and RABVs 
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primarily infect neurons, it is not likely that infected T or NK cells were a major 
source of RABV-encoded IFN in the CNS.  Therefore, during SPBN infection of 
mice, the production of IFN by classical immune cells does not appear to be 
essential for survival. Furthermore, the survival of SPBN-infected IFN-/- mice 
demonstrates that only virus-encoded IFN is necessary for protection and 
endogenous IFN production by NK or T cells is not required.  Together, these 
IFN-/- and JHD-/- data show that attenuation of RABV by IFN is profound in adult 
mice and it is not dependent upon the early production of VNA or an immune 
source of IFN.   
 
Analysis of our in vitro monocyte infection experiments leads us to consider that 
the stimulation of type I IFN expression by IFN contributes to survival from 
SPBN infection.  Experiments performed over the last several decades have 
questioned the importance of type I IFN during RABV infection.  Although some 
early experiments found type I IFN expression to be inconsequential to the fate of 
the RABV-infected animal (39) or equivocal (47), other reports suggest an 
important role for type I IFN (7, 48).  Measuring IFN levels late in the course of 
infection as well as focusing on survival as an estimation of IFN efficacy may 
have contributed to the confusion as to the importance of type I IFN.  One of the 
early experiments showed that there are two waves of type I IFN expression 
during wild-type RABV infection (40).  Very early expression of type I IFN is 
important for survival, while the second wave of expression is not therapeutic and 
is likely the result of uncontrolled RABV replication (40).  More recent work has 
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demonstrated that type I IFN can impede replication and spread of a highly 
neuroinvasive RABV both in vitro and in vivo and can delay/reduce mortality but 
cannot prevent death altogether (48).  Furthermore, an engineered RABV-based 
HIV vaccine vector expressing IFN is attenuated by its IFN production (49).  
Still other experiments have shown that attenuated RABV induce high levels of 
type I IFN while wild-type RABV do not (7).  Since type I IFN signaling is 
important for protection against infection, it is not surprising that the RABV virus 
itself dedicates substantial resources to blocking type I IFN signaling.  Both the N 
and P genes of RABV express products that interfere with type I IFN signaling 
(50, 51) and mutating P can attenuate the virus (52).  The blockade of type I IFN 
by RABV is a “leaky” process, however, and the host response is able to impede 
replication and spread to some degree despite this immunoevasion strategy (48). 
 
The attenuation of SPBN is profound in a number of wild-type mouse strains as 
well as those with severe immune deficits.  When we infected IFNAR-/- mice with 
SPBN, however, the overexpression of IFN could not compensate for this 
immune deficiency, and the mice quickly died.  This result again underscores the 
importance of type I IFN and suggests the mechanism by which SPBN is 
attenuated.  Together, our in vitro and in vivo data showing highly increased type 
I IFN expression from cell lines and brain tissue infected with SPBN over 
SPBN(-) as well as the lack of attenuation of SPBN in IFNAR-/- mice, suggest 
that expression of IFN induces the expression of type I IFN, and that enhancing 
type I IFN signaling plays a vital role in the attenuation of SPBN. 
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Although IFN induces hundreds of genes involved in other antiviral mechanisms, 
we have shown that a major mechanism of SPBN attenuation is through the 
induction of type I IFN.  This rapid type I IFN expression only occurs when an 
IFN-responsive cell is exposed to the virus.  This mechanism may circumvent  
the IFN evasion tactics of the RABV, leading to control of virus replication and 
spread and, ultimately, virus clearance.  
 
Altogether, our results indicate that the expression of IFN by RABV renders it 
attenuated even in mice with severe immune deficits.  The fact that the 
replication and spread of RABV in the CNS is controlled by immune mechanisms 
long before neutralizing antibody is produced has long been enigmatic in rabies 
and understanding the process may hold the key to therapy.  Our work shows 
that IFN produced early in the immune response to RABV likely uses innate 
mechanisms  to control the infection such that the later appearance of antibody 
can clear the infection. 
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FIGURE LEGENDS 
 
Figure 1. RABV constructs.  A, The negative-stranded RNA genome of the 
wild-type (WT) parental vector, SAD B19, which was used as the backbone to 
construct two RABV viruses used for all subsequent experiments.  The control 
virus, SPBN(-), which contains a cytokine gene (red crosshatch), inactivated by 
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the substitution of STOP codons for the initial seven START codons, is shown in 
B.  C represents the interferon gamma-expressing RABV, SPBN.  N, 
nucleoprotein; P, phosophoprotein; M, matrix protein; G, glycoprotein; L, large 
catalytic subunit of the viral polymerase; TGA, STOP codon; , murine IFN 
gene. 
 
Figure 2. IFN Production. NA cells were infected at an MOI=0.1 and stained 24 
hours later for the presence of RABV and IFN (A-C).  NA, AS and MC cells were 
infected at an MOI=1 and the supernatants were analyzed by IFN-specific 
ELISA 12 hours p.i.  A, uninfected control NA cells; B, SPBN(-)-infected cells; C, 
SPBN-infected cells.  D, IFN concentration in supernatants.  All photos are 
280x magnification.  Significance determined by student’s t test.  **, p0.01; ***, 
p0.001. 
 
Figure 3. Virus Growth Curves.  NA, AS and MC cell lines were infected with 
SPBN(-) or SPBN RABV at an MOI=1 for single step growth curves (A-C) and 
MOI=0.01 for multi-step growth curves (D-F).  Supernatant virus titers were 
measured at the indicated times post-infection. 
 
Figure 4. In vivo mouse infection.  Groups of ten Swiss-Webster mice were 
infected i.n. with SPBN or SPBN(-) RABV and monitored for mortality.  4A 
shows absolute survival proportions for each dose of virus used to calculate the 
LD50 in 4B.  4C is the Kaplan Meier plot indicating both death and time to death.  
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LD50 was calculated by the Habel Test for Potency.  Significant difference 
between survival curves was determined by the Mantel-Cox test.  ***, p0.001.  
#, LD50 for SPBN(-) could not be accurately calculated because all SPBN(-) 
doses killed more than 50% of mice. 
 
Figure 5. IFN expression and RABV replication in the brain.  Groups of five 
C57BL/6 mice were infected i.n. with SPBN or SPBN(-) RABV.  Ten d.p.i. brains 
were analyzed for the presence of specific mRNA.  A shows copies of viral 
nucleoprotein mRNA, while B shows copies of IFN mRNA.  C shows IFN/N 
expression illustrated as fold change in the brains of SPBN-infected as 
compared to control SPBN(-)-infected mice.  All copy numbers have been 
normalized to the L13 housekeeping gene.  Significance determined by the 
Mann-Whitney test.  **, p0.01. 
 
Figure 6.  Adaptive immune cell markers in the brain.  Groups of five 
C57BL/6 mice were infected i.n. with SPBN or SPBN(-) RABV.  Ten dpi brains 
were analyzed for the presence of specific mRNA.  Normalized mRNA copy 
numbers of CD4, CD8 and CD19 in the brains of RABV-infected mice are 
depicted in A, B and C, respectively.  All copy numbers are normalized to the L13 
housekeeping gene.  Significance determined by the Mann-Whitney test.  *, 
p0.05. 
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Figure 7.  Infection of IFN-/- and JHD-/- mice.  Groups of 8-9 IFN-/- mice (A 
and B) and groups of 13-14 JHD-/- mice (C and D) were infected i.n. with 105 ffu 
of SPBN(-) or SPBN and monitored for mortality and morbidity for 35 and 32 
days, respectively.  The survival curves are shown in A and C.  Weight loss as an 
indicator of infection is shown in B and D.  Significant difference between survival 
curves determined by the Mantel-Cox test.  Significant differences in weight loss 
determined by the student’s t test.  **, p0.01; ***, p0.001. 
 
Figure 8.  Infection of IFNAR-/- mice.  Groups of 6-7 WT129 (A) or IFNAR-/- (B) 
mice were infected i.n. with 105 ffu of SPBN or SPBN(-) and monitored for 
mortality and morbidity.  Significance was determined by the Mantel-Cox test.  
***, p0.001. 
 
Figure 9.  In vitro induction of type I interferon.  MC cells were infected with 
SPBN or SPBN(-) at an MOI=10.  In A, B, C cultures were analyzed at the 
indicated timepoints for levels of mRNA specific for RABV N versus IFN, IFN 
and IFN.  Bars represent normalized IFN mRNA levels plotted on the left Y axis 
and lines are normalized viral N mRNA expression plotted on the right Y axis.  
IFN was added to the cell cultures in D, E, F and virus titers (D) as well as IFN 
levels (E, F) assessed.  F shows IFN levels in the cultures at 24 hrs p.i. 
Significant differences in cytokine levels between SPBN(-) and SPBN infected 
cultures (A-C) and control versus treated cultures (F) were determined by 
student’s t test. 
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Figure 10.  In vivo induction of type I interferon.  Groups of C57BL/6 mice 
were infected i.n. with 105 ffu of SPBN or SPBN(-)and their brain sections were 
analyzed for the gene products denoted above.  Expression levels are 
normalized to the L13 housekeeping gene.  Significant differences were 
determined by the Mann-Whitney test.  *, p0.05; **, p0.01; ***, p0.001. 
 
